Avidian Wealth Enterprises LLC Has $847,000 Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Avidian Wealth Enterprises LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.5% during the 4th quarter, Holdings Channel.com reports. The firm owned 9,173 shares of the biopharmaceutical company’s stock after buying an additional 561 shares during the quarter. Avidian Wealth Enterprises LLC’s holdings in Gilead Sciences were worth $847,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. HHM Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 154 shares during the last quarter. nVerses Capital LLC bought a new stake in Gilead Sciences in the 3rd quarter worth about $25,000. YANKCOM Partnership bought a new position in shares of Gilead Sciences during the 4th quarter valued at approximately $28,000. Decker Retirement Planning Inc. bought a new position in shares of Gilead Sciences during the 4th quarter valued at approximately $29,000. Finally, Valued Wealth Advisors LLC grew its position in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 161 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares in the company, valued at $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now directly owns 8,920 shares in the company, valued at $815,198.80. This trade represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 572,824 shares of company stock worth $53,611,715. 0.16% of the stock is owned by company insiders.

Gilead Sciences Stock Up 7.5 %

Shares of Gilead Sciences stock opened at $103.31 on Thursday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The stock has a market capitalization of $128.75 billion, a PE ratio of 1,147.89, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $104.71. The company has a 50-day simple moving average of $93.14 and a two-hundred day simple moving average of $87.12.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. On average, analysts anticipate that Gilead Sciences, Inc. will post 4.35 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 3.06%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s payout ratio is 3,422.22%.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on GILD. Leerink Partnrs raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. JPMorgan Chase & Co. increased their target price on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Wolfe Research started coverage on shares of Gilead Sciences in a research report on Friday, November 15th. They set an “outperform” rating and a $110.00 target price for the company. BMO Capital Markets raised their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Royal Bank of Canada raised their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a report on Wednesday. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $101.04.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.